Rezolute, Inc. - RZLT STOCK NEWS

Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company, announced that CEO Nevan Charles Elam will present at two virtual investment conferences. The BTIG Virtual Biotechnology Conference is scheduled for August 10, 2021, at 12:00 p.m. ET, while the Canaccord Genuity 41st Annual Growth Conference will take place on August 12, 2021, at 3:30 p.m. ET. A live webcast for the latter will be available on the company’s Investors page, with a replay accessible for 90 days after the event.

Rezolute is focused on developing therapies for metabolic diseases, including its lead asset, RZ358, for congenital hyperinsulinism.

Rezolute, Inc. (Nasdaq: RZLT) has been added to the Russell Microcap® Index, effective June 28, 2021. This inclusion allows Rezolute to reach a broader investor base, as the Russell indexes are widely used for benchmarking in investment management. The Russell Microcap® Index listing lasts one year and enhances visibility for Rezolute’s therapeutic developments, particularly RZ358 for congenital hyperinsulinism and RZ402 for diabetic macular edema. With $10.6 trillion in assets benchmarked against Russell indexes, this move is expected to positively affect the company's market presence.

Rezolute, Inc. (Nasdaq: RZLT) has announced that CEO Nevan Charles Elam will present at two virtual investor conferences. The first event is the Jefferies Virtual Healthcare Conference on June 4, 2021, at 12:30 p.m. ET, followed by the JMP Securities Life Sciences Conference on June 17, 2021, at 1:30 p.m. ET. Interested parties can access live webcasts on the company's IR Calendar page, with replays available for 30 days afterward.

Rezolute is focused on developing treatments for metabolic diseases, specifically its lead asset RZ358 aimed at congenital hyperinsulinism.

Rezolute, Inc. (Nasdaq: RZLT) has appointed Davelyn Hood, MD, as Director of Scientific and Patient Affairs, enhancing its leadership team for the RZ358 clinical program targeting congenital hyperinsulinism. Dr. Hood brings over a decade of experience in the field and a personal connection to the disease as a parent of a child affected by it. RZ358, currently in a Phase 2b trial, aims to regulate insulin levels in patients with this rare condition. The therapy has received Orphan Drug and Pediatric Rare Disease designations in both the US and EU.

Rezolute, Inc. (RZLT), a clinical-stage biopharmaceutical company, has appointed Dr. Quan Dong Nguyen to its Scientific Advisory Board. Dr. Nguyen, a prominent expert in retinal diseases, will provide strategic counsel for RZ402, an oral plasma kallikrein inhibitor aimed at treating diabetic macular edema (DME). His extensive background includes leading pivotal clinical trials and contributing to the approval of existing therapies such as EYLEA and Lucentis. This addition is expected to enhance Rezolute's clinical development strategy and address unmet needs in DME treatment.

Rezolute, Inc. (RZLT), a clinical-stage biopharmaceutical company, reported its financial results for Q3 FY2021, ending March 31, 2021. The company continues to progress its pipeline, including RZ358 and RZ402. Topline results from a Phase 1 study of RZ402 indicate potential for daily oral dosing in diabetic macular edema treatment. Cash reserves stand at $32 million. R&D expenses rose slightly to $3.8 million, while G&A expenses increased to $1.7 million. The net loss for the quarter was $3.7 million ($0.44 per share), an improvement from a $5 million loss ($0.86 per share) in Q3 2020.

Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company, will present at the Oppenheimer Rare and Orphan Disease Summit on May 21, 2021. The presentation will be accessible on-demand at 8:00 AM ET and available for 90 days on the company’s Investors section. Rezolute is focused on developing novel therapies for chronic glucose imbalance, with its lead product, RZ358, undergoing Phase 2b trials for congenital hyperinsulinism. Additionally, RZ402 is being developed for diabetic macular edema. For more details, visit their website.

Rezolute, Inc. (Nasdaq: RZLT) announced positive topline results from its Phase 1a clinical study of RZ402, an oral plasma kallikrein inhibitor for diabetic macular edema (DME). The study showed that RZ402's single dose led to plasma concentrations significantly exceeding target levels, supporting the advancement to a Phase 1b study. The drug was generally safe and well-tolerated, with no serious adverse events reported. The results suggest RZ402 could provide an effective treatment option for DME patients, offering improved delivery and compliance.

Rezolute has secured a $30 million debt financing agreement with SLR Capital Partners to enhance its funding capabilities for advancing targeted therapies for rare and metabolic diseases. The initial $15 million was funded upon closing, with an interest-only period lasting 24 months. The remaining funds may be accessed upon meeting specific milestones. CEO Nevan Elam highlighted that this facility provides non-dilutive operational flexibility as they progress their pipeline, including lead candidate RZ358, currently in Phase 2b development.